SCHEMBL5794559

SCHEMBL5794559

O=C1c2c(c(O)c3nccnc3c2O)C(=O)N1C(c1ccccc1)c1cc2ccccc2o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 7/20 0.40
CYP26A1 O43174 2/20 0.40
BRD4 O60885 1/20 0.36
HPGD P15428 2/20 0.36
TYR P14679 1/20 0.36
DAO P14920 1/20 0.36
AKR1B1 P15121 1/20 0.36
PDE4D Q08499 1/20 0.35
ALDH1A1 P00352 3/20 0.35
RAB9A P51151 3/20 0.35
MAOB P27338 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
ESR1 P03372 1/20 0.34
GAPDH P04406 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ESR2 Q92731 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6101957 0.83 CYP19A1 (0.37) CYP19A1BRD4ALDH1A1KDM4ELMNA
SCHEMBL6101108 0.72 MAPT (0.39) BRD4HPGDALDH1A1L3MBTL1TSHR
SCHEMBL5768362 0.68 PDE4D (0.43) HPGDPDE4DALDH1A1RAB9AMAOB
SCHEMBL8696281 0.67 CYP19A1 (0.56) CYP19A1CYP26A1ALDH1A1RAB9ANPC1
SCHEMBL1906425 0.65 CYP19A1 (0.62) CYP19A1CYP26A1ALDH1A1RAB9ANPC1
SCHEMBL10362274 0.65 CYP19A1 (0.81) CYP19A1CYP26A1HPGDALDH1A1
SCHEMBL10838632 0.65 KDM4E (0.59) CYP19A1CYP26A1HPGDALDH1A1KDM4E
Hydrochloric Acid SCHEMBL10362740 0.64 CYP19A1 (0.79) CYP19A1CYP26A1HPGDALDH1A1
SCHEMBL10837642 0.63 CYP26A1 (0.46) CYP19A1CYP26A1HPGDALDH1A1KDM4E
SCHEMBL8700567 0.63 CYP26A1 (0.85) CYP19A1CYP26A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211724-A1 Hiv integrase inhibitors VERSCHUEREN GASTON W 2006-09-21 US disclosed
EP-1625130-A2 HIV INTEGRASE INHIBITORS Tibotec Pharmaceuticals Ltd. (IE) 2006-02-15 EP disclosed
WO-2004096807-A2 HIV INTEGRASE INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211724-A1 Hiv integrase inhibitors SULT1A1, SULT2A1, SULT1E1 CYP19A1 180/4885CYP26A1 70/4885BRD4 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.